<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30916125</article-id><article-id pub-id-type="pmc">6436780</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0231</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Expression of and Preoperative Correlation between Heat-Shock
Protein 70, EuroSCORE, and Lactate in Patients undergoing CABG with
Cardiopulmonary Bypass</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6431-8059</contrib-id><name><surname>Cantero</surname><given-names>Marcos Antonio</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, MSc</role></contrib><contrib contrib-type="author"><name><surname>Almeida</surname><given-names>Rui Manuel Siqueira</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Morato</surname><given-names>Priscila Neder</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MSc, PhD</role></contrib><contrib contrib-type="author"><name><surname>Santos-Junior</surname><given-names>Valfredo de Almeida</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MSc</role></contrib><contrib contrib-type="author"><name><surname>Moura</surname><given-names>Carolina Soares</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MSc, PhD</role></contrib><contrib contrib-type="author"><name><surname>Amaya-Farfan</surname><given-names>Jaime</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MSc, PhD</role></contrib><contrib contrib-type="author"><name><surname>Fonseca</surname><given-names>Jo&#x000e3;o Luis</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Lollo</surname><given-names>Pablo Christiano Barboza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MSc, PhD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Faculdade de Ci&#x000ea;ncias da Sa&#x000fa;de, Universidade Federal
da Grande Dourados, Dourados, MS, Brazil.</aff><aff id="aff2">
<label>2</label> Department of Cardiology and Cardiovascular Surgery, Universidade
Estadual do Oeste do Paran&#x000e1;, Cascavel, PR, Brazil.</aff><aff id="aff3">
<label>3</label> Faculdade de Engenharia de Alimentos, Universidade Estadual de
Campinas, Campinas, SP, Brazil.</aff><author-notes><corresp id="c1">Correspondence Address: <bold>Marcos Antonio Cantero</bold>,
http://orcid.org/0000-0001-6431-8059, Universidade Federal da Grande Dourados,
Jo&#x000e3;o Rosa G&#x000f3;es, 1762 - Dourados, MS, Brazil, Zip code: 79825-070.
E-mail: <email>marcoscantero@sbccv.org.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2019</year></pub-date><volume>34</volume><issue>2</issue><fpage>156</fpage><lpage>164</lpage><history><date date-type="received"><day>28</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>31</day><month>12</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objetive</title><p>Coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB)
improved symptoms and increased survival and quality of life in patients
with coronary artery disease. However, it should be the main cause of a
complex organic systemic inflammatory response that greatly contributes to
several postoperative adverse effects.</p></sec><sec><title>Methods</title><p>We aimed to evaluate heat-shock protein 70 (HSP 70) expression as a
morbimortality predictor in patients with preserved ventricular function
undergoing coronary artery bypass grafting (CABG) with cardiopulmonary
bypass (CPB) and to determine their association with the lactate as a marker
of tissue hypoperfusion and the EuroSCORE risk score. This is a prospective,
observational study including 46 patients and occurring between May and July
2016. Patients without ventricular dysfunction undergoing myocardial
revascularization with extracorporeal circulation were included. They were
divided into (1) complicated and (2) uncomplicated postoperative evolution
groups. EuroSCORE, lactate levels, and HSP 70 expression and their
correlations were determined.</p></sec><sec><title>Results</title><p>Statistical analysis showed that the group with complicated evolution had
higher EuroSCORE values than the other group. HSP 70 protein levels were
significantly increased in the group with uncomplicated evolution and showed
similar results. According to our results, HSP family proteins may be
independent predictors of uncomplicated evolution in patients without
ventricular dysfunction undergoing CABG with CPB.</p></sec><sec><title>Conclusion</title><p>HSP 70 should be a good discriminator and protection marker for complications
in cardiac surgery.</p></sec></abstract><kwd-group><kwd>HSP 70 Heat-Shock Proteins/Blood</kwd><kwd>Heat-Shock Proteins</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Cardiopulmonary Bypass</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Activated coagulation
time</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ATP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Adenosine
triphosphate</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interquartile range</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BSA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Body surface area</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Lower limit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">C</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Complicated</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">mRNA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Messenger ribonucleic
acid</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Non-complicated</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Odds ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CO<sub>2</sub></td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Carbon dioxide</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PMSF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Phenylmethanesulfonyl
fluoride</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ROC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Receiver operating
characteristic</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EDTA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">=
Ethylenediaminetetraacetic acid</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">UFGD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Federal University of
Grande Dourados</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Hb</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hemoglobin</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">UL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Upper limit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HSP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Heat-shock proteins</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">UNICAMP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= University of
Campinas</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HSP 70</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Heat-shock protein</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ventricular
fibrillation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IAB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">70&#x000a0;= Intra-aortic
balloon</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Coronary heart disease is the main cause of mortality in the global
population<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. In recent
decades, coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB)
have improved symptoms and increased survival rate and quality of life<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. However, this surgical method is
considered a cause of a complex organ system inflammatory response that contributes
to several postoperative adverse effects, which include renal, pulmonary,
neurological, and hemorrhagic complications<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In spite of significant changes and improvements in CPB
systems, complications involving tissue damage persist, affecting postoperative
morbidity and mortality<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.
Complications caused by CPB, such as bleeding, hemodilution, and low cardiac output,
are related to tissue hypoxia and organ dysfunctions<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>To assess morbidity and mortality during cardiac surgery, several models of risk
stratification have been developed<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>]</sup>. EuroSCORE is a simple, objective, effective, and
safe instrument even when applied to non-European populations<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. In Brazil, it is used as
postoperative morbidity and mortality predictor<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>. However, because
there are multiple and complex intraoperative and postoperative factors involved and
the prognosis needs to be safely assessed, it is necessary to evaluate tissue
perfusion by ideally simple and accessible methods that can provide information to
complement the EuroSCORE.</p><p>Lactate is widely used as a systemic indicator to evaluate the metabolism.
Nonetheless, its clinical interpretation should be cautious because although it
assesses the severity of the clinical situation, it is nonspecific, and the isolated
measurement does not benefit the prognostic evaluation<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Serial measurements and comparison of their
values provide a significant understanding of the case's severity<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p><p>Heat-shock proteins (HSP) belong to the chaperone family of proteins present in the
body cells. They correspond to approximately 1%-2% of the constituent proteins in
non-stressed cells and 4%-6% of the proteins in stressed cells. High molecular
weight HSP (HSP 100, 90, 70, and 60) are adenosine triphosphate (ATP)-dependent,
whereas low molecular weight HSP (HSP 20, 25, and 27) are ATP-independent<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. They provide the cell with great
tolerance and resistance against a variety of aggressor agents, maintaining the
cell's integrity and structure, besides promoting cell survival during stress
periods<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>Because HSP can respond to different types of stress, which include heart disease,
its potential as a diagnostic and prognostic marker in heart disease has been
proposed<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>There is a great interest in understanding the role of HSP in the inflammatory
response that occurs during cardiac surgery with CPB. Several studies have
demonstrated an increase in the production of pro-inflammatory cytokines after
CPB<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>.</p><p>Among the HSP types, HSP 70 is the most studied intracellular chaperone molecule.
Many efforts have been directed at assessing its capacity for protecting the cardiac
tissue undergoing ischemic preconditioning<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Experimental results suggest that the effect of moderate
hypothermia during CPB involves upregulation of HSP 70 with inhibition of necrosis,
but not of apoptosis<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. HSP 70
levels are associated with tissue damage and ischemia following cardiac surgery and
their measurement may present a diagnostic and prognostic advantage in these
cases<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p><p>Therefore, we aimed to evaluate HSP 70 expression as a morbimortality predictor in
patients with preserved ventricular function undergoing CABG with CPB and to
determine their association with the lactate as a marker of tissue hypoperfusion and
EuroSCORE risk score.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study Design and Protocol</title><p>The study protocol was evaluated and approved by the Graduate Teaching and
Research Committee of the Federal University of Grande Dourados (UFGD) and the
Ethics Committee for Analysis of Research Projects on Human Subjects of the
University of Campinas (UNICAMP). The protocol was registered on the 'Plataforma
Brasil' research website (CAAE Registry No. 50344015.8.3001.5404). A
prospective, observational study was conducted between May and July 2016 at the
Hospital Evang&#x000e9;lico Dr. e Sra. Goldsbyking (Dourados, MS, Brazil).</p><p>The patients were then divided into two groups, according to their postoperative
evolution: (1) patients with complicated evolution and (2) those with
uncomplicated evolution. Complicated evolution was defined as death during
hospitalization or in the first 30 days after surgery and/or the presence of one
or more postoperative complications that resulted in prolonged intensive care
unit (ICU) hospitalization (length of stay &#x0003e; 4 days). All other cases were
considered uncomplicated. The post-surgery outcomes were compared between the
groups.</p></sec><sec><title>Patients' Recruitment</title><p>During the study period, 93 patients scheduled to undergo cardiac surgery with
CPB in the institution were selected. After applying the exclusion criteria, 52
patients were considered eligible for the study. Among them, two patients did
not sign the informed consent form and four patients were excluded due to data
loss. Thus, 46 patients were included. The study inclusion criteria included
adult patients without left ventricular dysfunction who were scheduled to
undergo CABG with CPB. All subjects gave written informed consent to participate
in the study and were informed (orally and in detail) by the researchers about
the nature, investigative character, objectives, results, and risks of the
study.</p><p>The exclusion criteria comprehended patients with chronic or acute renal failure
(serum creatinine levels &#x02265; 1.4 g/dL), hepatic failure, uncontrolled
diabetes mellitus, pulmonary diseases (chronic obstructive pulmonary disease or
previous pulmonary surgery), neurological diseases (stroke, dementia, or
psychosis), history of fever or recent infection (up to 1 week prior to
surgery), presence of cardiogenic shock or mechanical complications of
infarction, abnormal ejection fraction (&#x0003c; 55%), and non-compliance with the
method on the part of the patient.</p></sec><sec><title>Surgery Protocol</title><p>The standard pre-anesthetic medication was 1 mg alprazolam, administered orally 8
hours before surgery; no medication was administered to patients with unstable
hemodynamic conditions. The anesthetic technique chosen was balanced general
anesthesia. After denitrogenation with 100% oxygen, anesthetic induction was
performed with etomidate (2 mg/kg), midazolam (0.05 mg/g), sufentanil (0.5
&#x000b5;g/kg), or fentanyl (5 &#x000b5;g/kg), and pancuronium (0.1 mg/kg) was
used as a neuromuscular blocker. The patients were then intubated and maintained
on mechanical ventilation with a fraction of inspired oxygen of 60% in the
valvular circulatory system with carbon dioxide (CO<sub>2</sub>) absorber,
volume-controlled and pressure-limited ventilation (25 mmHg), tidal volume
ranging from 6 to 8 mL/kg, respiratory rate of 12 cycles per minute, positive
end-expiratory pressure of 5 mmHg, and gas flow of 1.0 L/min. Anesthesia was
maintained using varying isoflurane concentrations (0.5%-1%) and intermittent
doses of sufentanil or fentanyl and pancuronium. Before CPB, a new aliquot of
midazolam and a neuromuscular blocker were administered.</p><p>Intraoperative hydration was performed with Ringer's lactate based on filling
pressures, diuresis, and cardiac output. The red blood cell transfusion
threshold was established as hemoglobin (Hb) &#x0003c; 7 mg/dL, in patients without
hemodynamic instability, and Hb &#x0003c; 9 mg/dL, in those with hemodynamic
instability.</p><p>Before CPB, patients underwent anticoagulation therapy with heparin
(Liquemine&#x000ae;) at a dose of 300 IU/kg to maintain activated coagulation
time (ACT) &#x0003e; 480 s, supplemented with doses of 5,000-10,000 IU when necessary
(ACT &#x0003c; 480 s). At the end of CPB, anticoagulation was reversed with protamine
hydrochloride at a 1:1 ratio of the initial dose. Patients underwent median
sternotomy; CPB was initiated with cannulation of the ascending aorta and right
atrium, and cannulation of the right upper pulmonary vein was initiated with the
introduction of a catheter for aspiration and decompression of the left
ventricle. Membrane oxygenators were used in all patients during CPB. The
temperature during CPB was maintained between 32&#x000b0;C and 34&#x000b0;C, and the myocardial
protection technique used was intermittent hypothermic antegrade cardioplegia.
The management of the acid-base balance during CPB was performed using the
alpha-stat method. Infusion was maintained with non-pulsatile flow of
approximately 2.2-2.4 L/min/m to maintain a mean blood pressure of approximately
60 mmHg.</p><p>To remove the patient from CPB, vasoactive and inotropic drugs were used
according to the patient's needs; this decision was left to the discretion of
the anesthesiologist.</p></sec><sec><title>Outcomes</title><p>The following preoperative clinical data were recorded: EuroSCORE; age; gender;
weight; body surface area (BSA); left ventricular ejection fraction; history of
previous cardiac surgeries; and use of intra-aortic balloon (IAB), inotropic
and/or vasopressor drugs, and nitroglycerin.</p><p>During surgery, the patient's temperature, heart rate, cardiac rhythm, urinary
output, arterial blood pressure (through the radial artery), and central venous
pressure (through the subclavian vein) were measured. Intraoperative data were
collected in the operating room, and postoperative data were collected in the
surgical ICU of the same institution. After surgery, patients were monitored
until discharge, and postoperative complications during the hospitalization
period were recorded.</p><p>The following postoperative complications were observed: prolonged hospital stay
(defined as hospital discharge after the 10th postoperative day), prolonged ICU
stay (defined as ICU discharge after the 4th postoperative day), prolonged
tracheal intubation time (defined as mechanical ventilation for more than 6
hours after admission to ICU or need for tracheal reintubation), neurological
complications (focal or global neurological deficit documented within 48 hours
after surgery or delirium), infectious complications (surgical wound infection,
mediastinitis, pneumonia, urinary tract infection, and/or sepsis with no
identified focus, according to the standards established by the Hospital
Infection Control Committee), low cardiac output (defined as a cardiac index
&#x0003c; 2.2 L/min/m<sup>2</sup>, difficulty in weaning from inotropic medications
24 hours after surgery, or the need for IAB use), arrhythmias (presence of
arrhythmia requiring the use of antiarrhythmic agents and/or the need for
defibrillation or electrical cardioversion), and acute kidney failure (defined
as an increase in serum creatinine levels &#x0003e; 50% of the preoperative value or
the need for hemodialysis).</p><p>Serum lactate levels were analyzed by arterial gasometry using the potentiometric
method, with a reference value of 5.7-2.0 mg/dL or 0.63-2.44 mmol/L. The
equipment used for the measurements was the Radiometer&#x000ae; ABL 700
gasometer.</p></sec><sec><title>Western Blot Analysis</title><p>Myocardial biopsy for HSP assessment was performed on the free wall of the right
atrium. The sample was obtained immediately after pericardial opening, prior to
the administration of heparin and/or any surgical manipulation of the heart.
Samples were preserved in liquid nitrogen and stored at -70&#x000b0;C until analysis.
The frozen samples were homogenized in 20 volumes of 600 mmol/L sodium chloride
and 15 mmol/L Tris (hydroxymethyl aminomethane); pH was 7.5. Protein levels were
determined using the technique described by Lowry et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> and bovine serum albumin was
used as a standard.</p><p>From each patient selected in this study, a 1 mL serum sample was collected
during atrial biopsy for assessing circulating HSP 70 levels. Next, 1 &#x000b5;L
of each protease inhibitor (phenylmethanesulfonyl fluoride [PMSF], aprotinin,
leupeptin) was added to each plasma aliquot prior to freezing in a -80&#x000b0;C
freezer. HSP 70 levels in the culture medium were determined using an
ultra-sensitive specific kit (HSP70 EKS-715), and the result was normalized by
the number of cells in each one and the incubation period, expressed as ng/h/108
cells.</p><p>The Western blot test was conducted as follows: the atrial muscle (200 mg) was
homogenized in 1 mL of buffer (200 mM ethylenediaminetetraacetic acid [EDTA]
[Sigma 03685], pH 7.0), 1 M Tris Base (Bio-Rad # 161-0719, pH 7.5), 10 mM
orthovanadate (Sigma S6508), 2 mM PMSF (Sigma P7626), 10 mM sodium pyrophosphate
(Sigma 221368), 0.1 mg/mL aprotinin (Sigma 10820), 100 mM sodium fluoride (Sigma
71519), 10% Triton (Sigma # 019K0151), and ultrapure water. The test used a
polytron (Pro Scientific model 200) and centrifuged the solution (Sigma, 2K15
model, serial number 57707, Germany) at 14,000 g for 40 min at 4&#x000b0;C; at this
point, the supernatant was collected. The total protein content in the
supernatant was determined using the Lowry method<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p></sec><sec><title>Statistical Analysis</title><p>In the statistical analysis, continuous variables were presented as means
&#x000b1; standard deviations or as medians and interquartile ranges when data
did not follow a Gaussian distribution. Categorical variables were presented as
proportions.</p><p>Continuous variables were analyzed using Student's t-test or non-parametric
Mann-Whitney test; categorical variables were analyzed using Fisher's exact test
or the chi-squared test, when appropriate. Parameters that presented a
difference between the groups with <italic>P</italic>&#x0003c;0.05 in the univariate
analysis were included in the multivariate analysis, which was performed using a
logistic regression model (backward Wald) to identify independent markers for
complicated evolution. The logistic regression results were described as
<italic>odds ratio</italic> (OR) and at a 95% confidence interval (95%
CI).</p><p>Receiver operating characteristic (ROC) curves of parameters identified as
complicated evolution predictors were constructed to find the best cut-off
points associated with complicated evolution. The cut-off point was determined
as the value associated with the highest sum of sensitivity and specificity.
Areas under the ROC curve were determined and compared. The analysis was
performed using the Statistical Package for Social Sciences software, version
17.0. A <italic>P</italic>-value &#x0003c; 0.05 was considered statistically
significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Of the 46 patients studied, 32 were men (69.5%) and 14 were women (30.4%). The ages
of the patients ranged from 35-83 years old. The general characteristics were
presented in <xref rid="t1" ref-type="table">Table 1</xref>. The mean age in the
group of patients with complications was 66.3 &#x000b1; 10 years while the mean age
in the group of those without complications was 59.7 &#x000b1; 9.4 years
(<italic>P</italic>=0.002). Although a different value was observed, there was
no statistically significant difference in BSA or in the proportion of female
patients between the groups.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>General characteristics of the patients' groups.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Uncomplicated evolution (n = 31)</th><th align="center" rowspan="1" colspan="1">Complicated evolution (n = 15)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">Test</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)<sup><xref ref-type="table-fn" rid="TFN1">a</xref></sup></td><td align="center" rowspan="1" colspan="1">59.7&#x000b1;9.4</td><td align="center" rowspan="1" colspan="1">66.3&#x000b1;10</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">Student's t-test</td></tr><tr><td align="left" rowspan="1" colspan="1">BSA (m<sup>2</sup>)<sup><xref ref-type="table-fn" rid="TFN1">a</xref></sup></td><td align="center" rowspan="1" colspan="1">1.81&#x000b1;0.17</td><td align="center" rowspan="1" colspan="1">1.71&#x000b1;0.16</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">Student's t-test</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)<sup><xref ref-type="table-fn" rid="TFN2">b</xref></sup></td><td align="center" rowspan="1" colspan="1">74 (65.5-80)</td><td align="center" rowspan="1" colspan="1">65 (60-73.5)</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">Mann-Whitney</td></tr><tr><td align="left" rowspan="1" colspan="1">Female gender<sup><xref ref-type="table-fn" rid="TFN3">c</xref></sup></td><td align="center" rowspan="1" colspan="1">8 (25.8%)</td><td align="center" rowspan="1" colspan="1">6 (40%)</td><td align="center" rowspan="1" colspan="1">0.13</td><td align="center" rowspan="1" colspan="1">Chi-squared</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction (VF)</td><td align="center" rowspan="1" colspan="1">58&#x000b1;1.3</td><td align="center" rowspan="1" colspan="1">56&#x000b1;1.2</td><td align="center" rowspan="1" colspan="1">0.25</td><td align="center" rowspan="1" colspan="1">Mann-Whitney</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>a</label><p>Values A1:E18 mean &#x000b1; standard deviation;</p></fn><fn id="TFN2"><label>b</label><p>median values and interquartile range;</p></fn><fn id="TFN3"><label>c</label><p>absolute value (percentages)</p></fn><fn id="TFN4"><p>BSA=body surface area; VF=ventricular fibrillation</p></fn></table-wrap-foot></table-wrap><p>The group with complicated evolution presented higher EuroSCORE values (median, 5;
interquartile range [IR], 3-5) than the group with uncomplicated evolution (median,
3; IR, 3-5). No differences were observed between the groups with respect to
surgery, anesthesia, aortic clamping, and CPB duration (<xref rid="t2" ref-type="table">Table 2</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Preoperative variables of patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Uncomplicated evolution (n=31)</th><th align="center" rowspan="1" colspan="1">Complicated evolution (n=15)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">Test</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">EuroSCORE<sup><xref ref-type="table-fn" rid="TFN5">b</xref></sup></td><td align="center" rowspan="1" colspan="1">3 (3-5)</td><td align="center" rowspan="1" colspan="1">6 (5-8)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">Mann-Whitney</td></tr><tr><td align="left" rowspan="1" colspan="1">IAB<sup><xref ref-type="table-fn" rid="TFN6">c</xref></sup></td><td align="center" rowspan="1" colspan="1">3 (6.1%)</td><td align="center" rowspan="1" colspan="1">4 (10.5%)</td><td align="center" rowspan="1" colspan="1">0.71</td><td align="center" rowspan="1" colspan="1">Fisher's test</td></tr><tr><td align="left" rowspan="1" colspan="1">Inotropic and/or vasopressor drugs<sup><xref ref-type="table-fn" rid="TFN6">c</xref></sup></td><td align="center" rowspan="1" colspan="1">1 (3.0%)</td><td align="center" rowspan="1" colspan="1">3 (20%)</td><td align="center" rowspan="1" colspan="1">0.44</td><td align="center" rowspan="1" colspan="1">Fisher's test</td></tr><tr><td align="left" rowspan="1" colspan="1">Nitroglycerin<sup><xref ref-type="table-fn" rid="TFN6">c</xref></sup></td><td align="center" rowspan="1" colspan="1">4 (13%)</td><td align="center" rowspan="1" colspan="1">2 (12.5%)</td><td align="center" rowspan="1" colspan="1">0.92</td><td align="center" rowspan="1" colspan="1">Fisher's test</td></tr><tr><td align="left" rowspan="1" colspan="1">Intraoperative</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Surgery duration</td><td align="center" rowspan="1" colspan="1">280 (240-340)</td><td align="center" rowspan="1" colspan="1">312 (245-374)</td><td align="center" rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">Mann-Whitney</td></tr><tr><td align="left" rowspan="1" colspan="1">Anesthesia duration</td><td align="center" rowspan="1" colspan="1">390 (320-430)</td><td align="center" rowspan="1" colspan="1">400 (334-480)</td><td align="center" rowspan="1" colspan="1">0.38</td><td align="center" rowspan="1" colspan="1">Mann-Whitney</td></tr><tr><td align="left" rowspan="1" colspan="1">CPB time (min)<sup><xref ref-type="table-fn" rid="TFN5">b</xref></sup></td><td align="center" rowspan="1" colspan="1">95 (75-118)</td><td align="center" rowspan="1" colspan="1">90 (69-140)</td><td align="center" rowspan="1" colspan="1">0.77</td><td align="center" rowspan="1" colspan="1">Mann-Whitney</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><label>b</label><p>Median values and interquartile range;</p></fn><fn id="TFN6"><label>c</label><p>absolute value (percentages)</p></fn><fn id="TFN7"><p>CPB=cardiopulmonary bypass; IAB=intra-aortic balloon</p></fn></table-wrap-foot></table-wrap><p>During the postoperative follow-up, 31 patients were classified as having
uncomplicated evolution (67.3%) and 15 patients had complicated evolution (32.6%),
three of whom died within 30 days of surgery, one of neurological complication and
two of infectious complications (<xref rid="t3" ref-type="table">Table 3</xref>).
The other postoperative parameters that configure the differences between the groups
were presented in <xref rid="t3" ref-type="table">Table 3</xref>.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparison between postoperative data of patients who underwent CABG with CPB
with uncomplicated and complicated evolutions.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Uncomplicated evolution (n=31)</th><th align="center" rowspan="1" colspan="1">Complicated evolution (n=15)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Duration of ICU stay (days)<sup><xref ref-type="table-fn" rid="TFN8">a</xref></sup></td><td align="center" rowspan="1" colspan="1">2 (2-4)</td><td align="center" rowspan="1" colspan="1">8 (7-21)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">In-hospital length of stay (days)<sup><xref ref-type="table-fn" rid="TFN8">a</xref></sup></td><td align="center" rowspan="1" colspan="1">7 (6-13)</td><td align="center" rowspan="1" colspan="1">21 (14-28)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Prolonged intubation<sup><xref ref-type="table-fn" rid="TFN9">b</xref></sup></td><td align="center" rowspan="1" colspan="1">18 (41%)</td><td align="center" rowspan="1" colspan="1">11 (75%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal complications<sup><xref ref-type="table-fn" rid="TFN9">b</xref></sup></td><td align="center" rowspan="1" colspan="1">1 (3%)</td><td align="center" rowspan="1" colspan="1">8 (51%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Neurological complications<sup><xref ref-type="table-fn" rid="TFN9">b</xref></sup></td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">4 (26%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Infectious complications<sup><xref ref-type="table-fn" rid="TFN9">b</xref></sup></td><td align="center" rowspan="1" colspan="1">9 (29%)</td><td align="center" rowspan="1" colspan="1">11 (73%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Low cardiac output<sup><xref ref-type="table-fn" rid="TFN9">b</xref></sup></td><td align="center" rowspan="1" colspan="1">3 (9.6%)</td><td align="center" rowspan="1" colspan="1">13 (86.6%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Arrhythmias<sup><xref ref-type="table-fn" rid="TFN9">b</xref></sup></td><td align="center" rowspan="1" colspan="1">2 (6.4%)</td><td align="center" rowspan="1" colspan="1">9 (60%)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN8"><label>a</label><p>Values in median and interquartile range;</p></fn><fn id="TFN9"><label>b</label><p>Absolute value (percentage)</p></fn><fn id="TFN10"><p>CABG=coronary artery bypass grafting; CPB=cardiopulmonary bypass;
ICU=intensive care unit</p></fn></table-wrap-foot></table-wrap><p>The area under the curve was 0.841 (95% CI: 0.725-0.956). This indicates that the
EuroSCORE has a high power to predict complications. The chance that a patient will
present complications increases by 2.09 times with each additional EuroSCORE point.
This is a strong independent risk and prognosis predictor, as shown in <xref ref-type="fig" rid="f1">Figure 1</xref>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>EuroSCORE receiver operating characteristic (ROC) curves to predict
complications.</p></caption><graphic xlink:href="rbccv-34-02-0156-g01"/></fig>
</p><p>Arterial lactate levels were significantly higher in the group with complicated
evolution than in the other group. Baseline levels of lactate were 452 &#x000b1; 88
in the uncomplicated group and 510 &#x000b1; 105 &#x000b5;M in the complicated group
(<italic>P</italic>=0.40). Despite being increased in the complicated group, the
delta lactate showed no significant difference in lactate levels between the groups.
The results indicate that there was a significant increase in arterial lactate
levels during surgery in both groups, but this was not an independent predictor of
complications. As shown in <xref ref-type="fig" rid="f2">Figure 2</xref>, the area
under the curve was 0.558 (95% CI: 0.386-0.73), and its accuracy was not significant
in this sample.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Lactate receiver operating characteristic (ROC) curves to predict
complications.</p></caption><graphic xlink:href="rbccv-34-02-0156-g02"/></fig>
</p><p>The significant increase in HSP 70 expression was observed in the group with
uncomplicated evolution. HSP 70 content was significantly higher in patients who did
not develop complication (34&#x000b1;12 <italic>vs</italic>. 18&#x000b1;14;
<italic>P</italic>=0.006). HSP 70 area under the curve was 0.683 (95% CI:
528-0.839), with a sensitivity of 93% of protection. These results held true even in
peripheral plasma (37&#x000b1;12 <italic>vs</italic>. 22&#x000b1;15,
<italic>P</italic>=0.01). HSP 70 presented the same expression in the peripheral
plasma with an area under the curve of 0.687 (95% CI: 0.377-0.715) and a significant
sensitivity of 93%, as observed in <xref ref-type="fig" rid="f3">Figures 3</xref>
and <xref ref-type="fig" rid="f4">4</xref>, respectively.</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Atrial heat-shock protein 70 (HSP 70) expressions receiver operating
characteristic (ROC) curves to predict complications.</p></caption><graphic xlink:href="rbccv-34-02-0156-g03"/></fig>
</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Serum heat-shock protein 70 (HSP 70) receiver operating characteristic
(ROC) curves to predict complications.</p></caption><graphic xlink:href="rbccv-34-02-0156-g04"/></fig>
</p><p>In our study, atrial biopsy was obtained immediately after opening the pericardium,
before administration of heparin-initiation of CPB. Inducible HSP 70 level in such
relatively unstressed atrial myocytes reflects initial expression of HSP 70 and
possibly represents a more efficient stress handling mechanism at the disposal of
these cells. Soluble HSP 70 concentrations may be a marker of cell injury induced by
severe stress and are not reflective of intracellular levels; this is the difference
in ROC curve for atrial <italic>vs</italic>. serum HSP 70 in <xref ref-type="fig" rid="f5">Figure 5</xref>.</p><p>
<fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Serum and atrial heat-shock protein 70 (HSP 70) receiver operating
characteristic (ROC) curves to predict complications.</p></caption><graphic xlink:href="rbccv-34-02-0156-g05"/></fig>
</p><p>From the univariate CI, it was observed that variable lactate levels were not risk
factors for patients with complications. Areas under the ROC curve demonstrate that
EuroSCORE and HSP 70 variables were protective factors for the occurrence of
complications. These findings indicate that EuroSCORE and HSP 70 variables presented
excellent discrimination power, as observed in <xref rid="t4" ref-type="table">Table
4</xref>.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Statistical analysis of the markers studied.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/><col width="11%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" colspan="4" rowspan="1">Univariate regression (95% CI)</th><th align="center" colspan="4" rowspan="1">Multivariate regression (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">OR</td><td align="center" rowspan="1" colspan="1">LL</td><td align="center" rowspan="1" colspan="1">UL</td><td align="center" rowspan="1" colspan="1"><italic>P</italic>-value</td><td align="center" rowspan="1" colspan="1">OR</td><td align="center" rowspan="1" colspan="1">LL</td><td align="center" rowspan="1" colspan="1">UL</td><td align="center" rowspan="1" colspan="1"><italic>P</italic>-value</td></tr><tr><td align="left" rowspan="1" colspan="1">EuroSCORE</td><td align="center" rowspan="1" colspan="1">2.097</td><td align="center" rowspan="1" colspan="1">1.326</td><td align="center" rowspan="1" colspan="1">3.316</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">1.99</td><td align="center" rowspan="1" colspan="1">1.259</td><td align="center" rowspan="1" colspan="1">3.147</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">Lactate</td><td align="center" rowspan="1" colspan="1">1.573</td><td align="center" rowspan="1" colspan="1">0.978</td><td align="center" rowspan="1" colspan="1">2.529</td><td align="center" rowspan="1" colspan="1">0.062</td><td align="center" rowspan="1" colspan="1">1.449</td><td align="center" rowspan="1" colspan="1">0.744</td><td align="center" rowspan="1" colspan="1">2.82</td><td align="center" rowspan="1" colspan="1">0.276</td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial HSP 70</td><td align="center" rowspan="1" colspan="1">0.787</td><td align="center" rowspan="1" colspan="1">0.666</td><td align="center" rowspan="1" colspan="1">0.929</td><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">1.146</td><td align="center" rowspan="1" colspan="1">0.71</td><td align="center" rowspan="1" colspan="1">1.85</td><td align="center" rowspan="1" colspan="1">0.577</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum HSP 70</td><td align="center" rowspan="1" colspan="1">0.71</td><td align="center" rowspan="1" colspan="1">0.501</td><td align="center" rowspan="1" colspan="1">1.004</td><td align="center" rowspan="1" colspan="1">0.053</td><td align="center" rowspan="1" colspan="1">1.25</td><td align="center" rowspan="1" colspan="1">0.704</td><td align="center" rowspan="1" colspan="1">2.219</td><td align="center" rowspan="1" colspan="1">0.446</td></tr></tbody></table><table-wrap-foot><fn id="TFN11"><p>CI=confidence interval; HSP 70=heat-shock protein 70; LL=lower limit;
OR=odds ratio; UL=upper limit</p></fn></table-wrap-foot></table-wrap><p>The qualitative expression of HSP 70 showed that the level of protein was correlated
to the outcome of post-surgery evolution, as shown in the <xref ref-type="fig" rid="f6">Figure 6</xref>. The non-complicated group showed higher bands
expressions of serum and atrial HSP 70 levels (<xref ref-type="fig" rid="f7">Figure
7</xref>) than the complicated group.</p><p>
<fig id="f6" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Myocardial expression of heat-shock protein 70 (HSP 70) and evolution
outcome. C=complicated; NC=non-complicated</p></caption><graphic xlink:href="rbccv-34-02-0156-g06"/></fig>
</p><p>
<fig id="f7" orientation="portrait" position="float"><label>Fig. 7</label><caption><p>Atrial and serum heat-shock protein 70 (HSP 70) expression in the
complicated (C) and non-complicated (NC) group. BSA=body surface
area</p></caption><graphic xlink:href="rbccv-34-02-0156-g07"/></fig>
</p><p>The dispersion plot of correlation between serum and atrial HSP 70 expression showed
a moderate and non-significant coefficient of relationship
(<italic>P</italic>&#x0003e;0.05) (<xref ref-type="fig" rid="f8">Figure 8</xref>). Linear
regression equation is presented in the <xref ref-type="fig" rid="f8">Figure
8</xref>.</p><p>
<fig id="f8" orientation="portrait" position="float"><label>Fig. 8</label><caption><p>Linear regression between serum and atrial heat-shock protein 70 (HSP) 70
expression.</p></caption><graphic xlink:href="rbccv-34-02-0156-g08"/></fig>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>CABG with CPB is a highly effective treatment for coronary insufficiency; however, it
has a non-negligible potential for complications. The identification of markers of
these complications can minimize or even prevent them and the HSP 70 expression
seems to be a good way to measure the complication risk. This study evaluated the
expression of HSP 70 in the myocardium and peripheral blood and its association with
postoperative evolution. This protein shows a low expression in patients with
complicated evolution.</p><p>EuroSCORE consists of a risk stratification model developed for predicting hospital
mortality after cardiac surgery<sup>[<xref rid="r7" ref-type="bibr">7</xref>-<xref rid="r9" ref-type="bibr">9</xref>]</sup>, and it was an independent
predictor of complicated evolution for this patient population. Several studies have
demonstrated the validity of its use as a predictor of postoperative morbidity in
cardiac surgery<sup>[<xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup> and the results of the present study are in
agreement with the literature. The chance of complication increased by 2.09 times
with each increased unit of EuroSCORE; values &#x0003e; 5 were predictors of complicated
evolution in patients with normal ventricular function who underwent myocardial
revascularization. EuroSCORE has also presented excellent sensitivity for the
detection of complications in patients undergoing CABG in this population<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Present data confirm these findings, with a sensitivity of
&#x0003e; 90%.</p><p>The arterial lactate level tended to be higher in the group with complicated
evolution than in the group with uncomplicated evolution, although no statistically
significant differences were observed. Approximately 10%-20% of patients present
high lactate levels and postoperative morbimortality<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Although there was an increase in lactate levels
in the group with complicated evolution, it was not consistent enough to be
considered as an independent prognosis predictor. This absence of statistical
significance may be explained by the limitation of the analysis, which was
restricted to the intraoperative period. This period was too short to allow for
arterial lactate clearance or to study its kinetics.</p><p>The results of this study suggest that HSP 70 is an independent uncomplicated
evolution predictor after myocardial revascularization in patients with normal left
ventricular function. This marker presented a sensitivity of &#x0003e; 93%, which
constitutes a protection factor.</p><p>High levels of HSP 70 are related to lower damage caused by ischemia<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. The presence of postoperative
complication seems to be associated with low levels of HSP70. After inducing HSP 70
overexpression, Okubo et al. demonstrated a significant reduction in the infracted
area<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. The ischemic
heart appears to be less capable of producing HSP 70, a factor which could be
closely related to the decrease of the ability to tolerate stress after a
surgery<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. Experimental
results suggest that the effect of moderate hypothermia during CPB involves the
regulation of the HSP 70 protein family, with the inhibition of necrosis, but not of
apoptosis<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>. HSP 70
levels have previously been associated with tissue damage and ischemia following
cardiac surgery, and its measurement may be a diagnostic and prognostic advantage in
these cases<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p><p>The differences in HSP 70 expression and its correlation with postoperative evolution
may be influenced by the groups, since ageing negatively regulate the HSP 70
expression in heart and can cause the heart to be more susceptible to oxidative and
stress damage<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>. This can
reinforce our argument that an increase in HSP 70 expression should be a
cardioprotection mechanism, because the complicated evolution group showed higher
age. The other possible influence was the group's sex prevalence. Sex hormone alters
the expression of HSP 70 differently in women and men<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. However, it's unclear if the men are more
sensitive to induction of HSP 70 expression by the inhibitory effect of estrogen on
the HSP 70 expression<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup> or if
the women hormone doesn't have this inhibitory effect and other factors are involved
in upregulation of HSP 70 expression<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>.</p><p>Circulating HSP 70 may indicate cellular stress or damage. Furthermore, HSP are
suggested as immunoregulatory agents, and may be important in the host defense
postoperatively<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>. The
effects of two different cardioplegia techniques on myocardial HSP 70 messenger
ribonucleic acid (mRNA) levels suggest that there was a significant increase in HSP
70 mRNA levels in response to CPB in both groups<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>. However, we didn't find a causal correlation
between atrial and serum HSP 70 expression. The inductions of expression of this
protein are tissue-specific and the circulation levels can be influenced by other
origins. New study researches should explore if the increase in the HSP 70 cardiac
expression may positively or negatively regulate the serum protein expressions.</p><p>The mechanism of HSP 70 expression preconditioning to increase success of cardiac
surgery interventions is unclear but the present findings suggest that because HSP
70 levels are inherently high in patients with more favorable evolution and there is
a correction with EuroSCORE, any protective benefit that can be derived from this
protein can already be measured. This is in agreement with the literature<sup>[<xref rid="r32" ref-type="bibr">32</xref>]</sup>. The development of mechanisms
that increase tolerance to perioperative damage may result in a more advanced method
to attenuate CPB-induced inflammation and minimize this problem; measures that
increase HSP 70 expression can be part of these mechanisms.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The present findings demonstrate that some predictors, such as EuroSCORE, are
independent complication predictors. Furthermore, the myocardial or serum HSP 70
levels can be considered as independent predictors of uncomplicated evolution in
patients without ventricular dysfunction who undergo CABG, thereby providing
additional information on the prognosis of these patients.</p><p>We conclude that the HSP 70, whether myocardial or serum (the latter being more
feasible to measure), may be a relevant biomarker. A better understanding of the
role of HSP in the inflammation caused by CPB may provide the possibility of
predicting and helping prevent an adverse event in the immediate postoperative
period following cardiac surgery.</p><p>It is believed that the identification of patients at high risk of complications
during cardiac surgery using scores and known markers, associated with other
predictors with strong predictive power, may allow for the adoption of early
measures aimed at better tissue perfusion, resulting in a shorter ICU stay and
better prognosis for patients undergoing myocardial revascularization.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MAC</td><td align="left" rowspan="1" colspan="1">Design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">RMSA</td><td align="left" rowspan="1" colspan="1">Drafting the work and revising it critically for
important intellectual content; final approval of the version to be
published</td></tr><tr><td align="left" rowspan="1" colspan="1">PNM</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the acquisition of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">VASJ</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the acquisition of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">CSM</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the acquisition of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">JAF</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the acquisition of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">JLF</td><td align="left" rowspan="1" colspan="1">Substantial contributions to the acquisition of data
for the work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">PCBL</td><td align="left" rowspan="1" colspan="1">Design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Faculdade de Ci&#x000ea;ncias da Sa&#x000fa;de,
Universidade Federal da Grande Dourados, Dourados, MS, Brazil.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>OECD: Organization for Economic Co-operation and
Development</collab></person-group><source>Version 06/26/2015. Health Data 2015: Statistics and indicators for 30
countries</source><comment>[Internet]</comment><publisher-loc>Paris</publisher-loc><publisher-name>OCED</publisher-name><year>2015</year><date-in-citation content-type="access-date">2019 Feb 27</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://oecd.org/health/healthdata">http://oecd.org/health/healthdata</ext-link></comment></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Zucker</surname><given-names>D</given-names></name><name><surname>Peduzzi</surname><given-names>P</given-names></name><name><surname>Fisher</surname><given-names>LD</given-names></name><name><surname>Takaro</surname><given-names>T</given-names></name><name><surname>Kennedy</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Effect of coronary artery bypass graft surgery on survival:
overview of 10-year results from randomized trials by the Coronary Artery
Bypass Graft Surgery Trialist Collaboration</article-title><source>Lancet</source><year>1994</year><volume>344</volume><issue>8922</issue><fpage>563</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">7914958</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>M</given-names></name><name><surname>Stamler</surname><given-names>A</given-names></name><name><surname>Sahar</surname><given-names>G</given-names></name><name><surname>Georghiou</surname><given-names>GP</given-names></name><name><surname>Sharoni</surname><given-names>E</given-names></name><name><surname>Brauner</surname><given-names>R</given-names></name><etal/></person-group><article-title>Validation of the 2000 Bernstein-Parsonnet score versus the
EuroSCORE as a prognostic tool in cardiac surgery</article-title><source>Ann Thorac Surg</source><year>2006</year><volume>81</volume><issue>2</issue><fpage>537</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">16427846</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moura</surname><given-names>HV</given-names></name><name><surname>Pomerantzeff</surname><given-names>PMA</given-names></name><name><surname>Gomes</surname><given-names>WJ</given-names></name></person-group><article-title>S&#x000ed;ndrome da resposta inflamat&#x000f3;ria sist&#x000ea;mica
na circula&#x000e7;&#x000e3;o extracorp&#x000f3;rea: papel das
interleucinas</article-title><source>Rev Bras Cir Cardiovasc</source><year>2001</year><volume>16</volume><issue>4</issue><fpage>376</fpage><lpage>387</lpage></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiolero</surname><given-names>RL</given-names></name><name><surname>Revelly</surname><given-names>JP</given-names></name><name><surname>Leverve</surname><given-names>X</given-names></name><name><surname>Gersbach</surname><given-names>P</given-names></name><name><surname>Cayeux</surname><given-names>MC</given-names></name><name><surname>Berger</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Effects of cardiogenic shock on lactate and glucose metabolism
after heart surgery</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><issue>12</issue><fpage>3784</fpage><lpage>3791</lpage><pub-id pub-id-type="pmid">11153615</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranucci</surname><given-names>M</given-names></name><name><surname>De Toffol</surname><given-names>B</given-names></name><name><surname>Isgro</surname><given-names>G</given-names></name><name><surname>Romitti</surname><given-names>F</given-names></name><name><surname>Conti</surname><given-names>D</given-names></name><name><surname>Vicentini</surname><given-names>M</given-names></name></person-group><article-title>Hyperlactatemia during cardiopulmonary bypass: determinants and
impact on postoperative outcome</article-title><source>Crit Care</source><year>2006</year><volume>10</volume><issue>6</issue><fpage>R167</fpage><lpage>R167</lpage><pub-id pub-id-type="pmid">17134504</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name><name><surname>Gauducheau</surname><given-names>E</given-names></name><name><surname>Lemeshow</surname><given-names>S</given-names></name><name><surname>Salamon</surname><given-names>R</given-names></name></person-group><article-title>European system for cardiac operative risk evaluation
(EuroSCORE)</article-title><source>Eur J Cardiothorac Surg</source><year>1999</year><volume>16</volume><issue>1</issue><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10456395</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Algotsson</surname><given-names>L</given-names></name><name><surname>Hoglund</surname><given-names>P</given-names></name><name><surname>Luhrs</surname><given-names>C</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name></person-group><article-title>EuroSCORE predicts intensive care unit stay and costs of open
heart surgery</article-title><source>Ann Thorac Surg</source><year>2004</year><volume>78</volume><issue>5</issue><fpage>1528</fpage><lpage>1534</lpage><pub-id pub-id-type="pmid">15511424</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campagnucci</surname><given-names>VP</given-names></name><name><surname>Pereira</surname><given-names>WL</given-names></name><name><surname>Chamlian</surname><given-names>EG</given-names></name><name><surname>Gandra</surname><given-names>SM</given-names></name><name><surname>Rivetti</surname><given-names>LA</given-names></name></person-group><article-title>EuroSCORE and the patients undergoing coronary bypass surgery at
Santa Casa de Sao Paulo</article-title><source>Rev Bras Cir Cardiovasc</source><year>2008</year><volume>23</volume><issue>2</issue><fpage>262</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">18820791</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moraes</surname><given-names>F</given-names></name><name><surname>Duarte</surname><given-names>C</given-names></name><name><surname>Cardoso</surname><given-names>E</given-names></name><name><surname>Ten&#x000f3;rio</surname><given-names>E</given-names></name><name><surname>Pereira</surname><given-names>V</given-names></name><name><surname>Lampreia</surname><given-names>D</given-names></name><etal/></person-group><article-title>Avalia&#x000e7;&#x000e3;o do EuroSCORE como preditor de mortalidade
em cirurgia de revasculariza&#x000e7;&#x000e3;o mioc&#x000e1;rdica no Instituto
do Cora&#x000e7;&#x000e3;o de Pernambuco</article-title><source>Rev Bras Cir Cardiovasc</source><year>2006</year><volume>21</volume><issue>1</issue><fpage>29</fpage><lpage>34</lpage></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakker</surname><given-names>J</given-names></name><name><surname>Gris</surname><given-names>P</given-names></name><name><surname>Coffernils</surname><given-names>M</given-names></name><name><surname>Kahn</surname><given-names>RJ</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Serial blood lactate levels can predict the development of
multiple organ failure following septic shock</article-title><source>Am J Surg</source><year>1996</year><volume>171</volume><issue>2</issue><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">8619454</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manikis</surname><given-names>P</given-names></name><name><surname>Jankowski</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Kahn</surname><given-names>RJ</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name></person-group><article-title>Correlation of serial blood lactate levels to organ failure and
mortality after trauma</article-title><source>Am J Emerg Med</source><year>1995</year><volume>13</volume><issue>6</issue><fpage>619</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">7575797</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diller</surname><given-names>KR</given-names></name></person-group><article-title>Stress protein expression kinetics</article-title><source>Annu Rev Biomed Eng</source><year>2006</year><volume>8</volume><fpage>403</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">16834562</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>MG</given-names></name></person-group><article-title>Heat shock factors and the control of the stress
response</article-title><source>Biochemi Pharmacol</source><year>2000</year><volume>59</volume><issue>1</issue><fpage>55</fpage><lpage>63</lpage></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Heat shock protein 70 acts as a potential biomarker for early
diagnosis of heart failure</article-title><source>PLoSOne</source><year>2013</year><volume>8</volume><issue>7</issue><elocation-id>e67964</elocation-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>TJ</given-names></name><name><surname>Sievers</surname><given-names>RE</given-names></name><name><surname>Vissern</surname><given-names>FL</given-names></name><name><surname>Welch</surname><given-names>WJ</given-names></name><name><surname>Wolfe</surname><given-names>CL</given-names></name></person-group><article-title>Heat shock protein induction in rat hearts: A role for improved
myocardial salvage after ischemia and reperfusion</article-title><source>Circulation</source><year>1992</year><volume>85</volume><issue>2</issue><fpage>769</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">1735169</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>SL</given-names></name></person-group><source>Temas atuais em circula&#x000e7;&#x000e3;o extracorp&#x000f3;rea</source><chapter-title>S&#x000ed;ndrome de resposta inflamat&#x000f3;ria sist&#x000ea;mica
p&#x000f3;s circula&#x000e7;&#x000e3;o extracorp&#x000f3;rea</chapter-title><person-group person-group-type="editor"><name><surname>Teixeira Filho</surname><given-names>GF</given-names></name></person-group><comment>Temas atuais em circula&#x000e7;&#x000e3;o extracorp&#x000f3;rea</comment><year>1997</year><publisher-loc>Porto Alegre</publisher-loc><publisher-name>Ponto um Gr&#x000e1;fica</publisher-name><fpage>90</fpage><lpage>97</lpage></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yellon</surname><given-names>DM</given-names></name><name><surname>Latchman</surname><given-names>DS</given-names></name><name><surname>Marber</surname><given-names>MS</given-names></name></person-group><article-title>Stress proteins: an endogenous route to myocardial
protection-fact or fiction?</article-title><source>Cardiovasc Res</source><year>1993</year><volume>27</volume><fpage>158</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">8472265</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qing</surname><given-names>M</given-names></name><name><surname>Vazquez-Jimenez</surname><given-names>JF</given-names></name><name><surname>Schumacher</surname><given-names>K</given-names></name><name><surname>Bhardwaj</surname><given-names>RS</given-names></name><name><surname>Klosterhalfen</surname><given-names>B</given-names></name><name><surname>Minkenberg</surname><given-names>R</given-names></name><etal/></person-group><article-title>Moderate hypothermia during cardiopulmonary bypass increases
intramyocardial synthesis of heat shock protein 72</article-title><source>J Thorac Cardiovasc Surg</source><year>2002</year><volume>124</volume><issue>4</issue><fpage>724</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">12324730</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dybdahl</surname><given-names>B</given-names></name><name><surname>Wahba</surname><given-names>A</given-names></name><name><surname>Lien</surname><given-names>E</given-names></name><name><surname>Flo</surname><given-names>TH</given-names></name><name><surname>Waage</surname><given-names>A</given-names></name><name><surname>Qureshi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Inflammatory response after open heart surgery: release of
heat-shock protein 70 and signaling through toll-like
receptor-4</article-title><source>Circulation</source><year>2002</year><volume>105</volume><issue>6</issue><fpage>685</fpage><lpage>690</lpage><pub-id pub-id-type="pmid">11839622</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowry</surname><given-names>OH</given-names></name><name><surname>Rosebrough</surname><given-names>NJ</given-names></name><name><surname>Farr</surname><given-names>AL</given-names></name><name><surname>Randall</surname><given-names>RJ</given-names></name></person-group><article-title>Protein measurement with the Folinphenol reagent</article-title><source>J Biol Chem</source><year>1951</year><volume>193</volume><issue>1</issue><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">14907713</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toumpoulis</surname><given-names>IK</given-names></name><name><surname>Anagnostopoulos</surname><given-names>CE</given-names></name><name><surname>Swistel</surname><given-names>DG</given-names></name><name><surname>DeRose</surname><given-names>JJ</given-names></name></person-group><article-title>Does EuroSCORE predict length of stay and specific postoperative
complications after cardiac surgery?</article-title><source>Eur J Cardiothorac Surg</source><year>2005</year><volume>27</volume><issue>1</issue><fpage>128</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">15621484</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirose</surname><given-names>H</given-names></name><name><surname>Inaba</surname><given-names>H</given-names></name><name><surname>Noguchi</surname><given-names>C</given-names></name><name><surname>Tambara</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Yamasaki</surname><given-names>M</given-names></name><etal/></person-group><article-title>EuroSCORE predicts postoperative mortality, certain morbidities,
and recovery time</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2009</year><volume>9</volume><issue>4</issue><fpage>613</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">19596705</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okubo</surname><given-names>S</given-names></name><name><surname>Wildner</surname><given-names>O</given-names></name><name><surname>Shah</surname><given-names>MR</given-names></name><name><surname>Chelliah</surname><given-names>JC</given-names></name><name><surname>Hess</surname><given-names>ML</given-names></name><name><surname>Kukreja</surname><given-names>RC</given-names></name></person-group><article-title>Gene transfer of heat-shock protein 70 reduces infarct size in
vivo after ischemia/reperfusion in the rabbit heart</article-title><source>Circulation</source><year>2001</year><volume>103</volume><issue>6</issue><fpage>877</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">11171798</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanonaka</surname><given-names>K</given-names></name><name><surname>Furuhama</surname><given-names>KI</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Kakuta</surname><given-names>K</given-names></name><name><surname>Miyamoto</surname><given-names>Y</given-names></name><name><surname>Toga</surname><given-names>W</given-names></name><etal/></person-group><article-title>Protective effect of heat shock protein 72 on contractile
function of perfused failing heart</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2001</year><volume>281</volume><issue>1</issue><fpage>H215</fpage><lpage>H222</lpage><pub-id pub-id-type="pmid">11406488</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinaldi</surname><given-names>B</given-names></name><name><surname>Corbi</surname><given-names>G</given-names></name><name><surname>Boccuti</surname><given-names>S</given-names></name><name><surname>Filippelli Wm Rengo</surname><given-names>G</given-names></name><name><surname>Leosco</surname><given-names>D</given-names></name><etal/></person-group><article-title>Exercise training affects age-induced changes in SOD and heat
shock protein expression in rat heart</article-title><source>Exp Gerontol</source><year>2006</year><volume>41</volume><issue>8</issue><fpage>764</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">16822632</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos-Junior</surname><given-names>VA</given-names></name><name><surname>Lollo</surname><given-names>PCB</given-names></name><name><surname>Cantero</surname><given-names>MA</given-names></name><name><surname>Moura</surname><given-names>CA</given-names></name><name><surname>Amaya-Farfan</surname><given-names>J</given-names></name><name><surname>Morato</surname><given-names>PN</given-names></name></person-group><article-title>Heat Shock Proteins: Protection and Potential Biomarkers for
Ischemic Injury of Cardiomyocytes After Surgery</article-title><source>Braz J Cardiovasc Surg</source><year>2018</year><volume>33</volume><issue>3</issue><fpage>291</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">30043923</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinohara</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Ooie</surname><given-names>T</given-names></name><name><surname>Ichinose</surname><given-names>M</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Yonemochi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Estrogen inhibits hyperthermia-induced expression of heat-shock
protein 72 and cardioprotection against ischemia/reperfusion injury in
female rat heart</article-title><source>J Mol Cell Cardiol</source><year>2004</year><volume>37</volume><issue>5</issue><fpage>1053</fpage><lpage>1061</lpage><pub-id pub-id-type="pmid">15522282</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowlton</surname><given-names>AA</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name></person-group><article-title>Heat-shock factor-1, steroid hormones and regulation of heat
shock protein expression in the heart</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2001</year><volume>280</volume><issue>1</issue><fpage>H455</fpage><lpage>H464</lpage><pub-id pub-id-type="pmid">11123263</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dybdahl</surname><given-names>B</given-names></name><name><surname>Wahba</surname><given-names>A</given-names></name><name><surname>Haaverstad</surname><given-names>R</given-names></name><name><surname>Kirkeby-Garstad</surname><given-names>I</given-names></name><name><surname>Kierulf</surname><given-names>P</given-names></name><name><surname>Espevik</surname><given-names>T</given-names></name><name><surname>Sundan</surname><given-names>A</given-names></name></person-group><article-title>On-pump versus off-pump coronary artery bypass grafting: more
heat-shock protein 70 is released after on-pump surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2004</year><volume>25</volume><issue>6</issue><fpage>985</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">15144999</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yavuz</surname><given-names>S</given-names></name><name><surname>Kasap</surname><given-names>M</given-names></name><name><surname>Parlar</surname><given-names>H</given-names></name><name><surname>Agirbas</surname><given-names>H</given-names></name><name><surname>Torol</surname><given-names>S</given-names></name><name><surname>Kanli</surname><given-names>A</given-names></name><name><surname>Hosten</surname><given-names>T</given-names></name><name><surname>Kanko</surname><given-names>M</given-names></name><name><surname>Berki</surname><given-names>T</given-names></name></person-group><article-title>Heat Shock Proteins and Myocardial Protection during
Cardiopulmonary Bypass</article-title><source>J Int Med Res</source><year>2011</year><volume>39</volume><issue>2</issue><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">21672353</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szerafin</surname><given-names>T</given-names></name><name><surname>Hoetzenecker</surname><given-names>K</given-names></name><name><surname>Hacker</surname><given-names>S</given-names></name><name><surname>Horvath</surname><given-names>A</given-names></name><name><surname>Pollreisz</surname><given-names>A</given-names></name><name><surname>Arpad</surname><given-names>P</given-names></name><etal/></person-group><article-title>Heat Shock Proteins 27, 60, 70, 90a, and 20S Proteasome in
On-Pump Versus Off-Pump Coronary Artery Bypass Graft
Patients</article-title><source>Ann Thorac Surg</source><year>2008</year><volume>85</volume><issue>1</issue><fpage>80</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">18154785</pub-id></element-citation></ref></ref-list></back></article>